Radioligand Therapies - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036

Key Highlights:

• According to DelveInsight, Radioligand Therapy Market is expected to grow rapidly by 2036.
• LUTATHERA recorded more than USD 450 million in sales in the first nine months of 2023, with a growth rate of 34% year over year and Novartis believes LUTATHERA could notch more than USD 1 billion in peak sales as a first-line therapy.
• Upon approval in 2022, PLUVICTO generated full-year sales standing at USD 980 million and the PSMA-directed therapy barely missed its chance at reaching blockbuster status in its first full year.
• Leading radioligand therapies companies, such as Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others, are developing novel radioligand therapies that can be available in the radioligand therapies market in the coming years.

Radioligand Therapy Market Insights and Trends

• In 2018, the US FDA approved LUTATHERA (lutetium Lu 177 dotatate) and it became the first Radioligand Therapy Market Driver or radiopharmaceutical that has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Then, in 2024, the FDA approved it as the first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors.
• Radioligand therapy is an innovative treatment approach, which is administered through an intravenous infusion. It combines the power of radioisotopes with a target-seeking ligand to deliver radiation to cancer cells expressing a specific target, even when they have spread throughout the body. With RLT, the goal is to deliver the treatment to the target cells to damage or destroy those cells while limiting impact to surrounding cells.
• Moreover, several Radioligand Therapy is currently being evaluated in clinical trials. An example is Lilly's, Lu-PNT2002 which is in the developmental stage and is anticipated to receive approval during the forecast period.

Factors Affecting Radioligand Therapy Market Growth

• Rising Global Cancer Burden: The increasing prevalence of cancers such as prostate cancer and neuroendocrine tumors (NETs) is a major factor driving demand for radioligand therapies. These therapies are particularly effective in treating cancers that are difficult to manage with conventional treatments like chemotherapy or external radiation.
• Growing Demand for Targeted and Precision Oncology: Radioligand therapies deliver radioactive isotopes directly to tumor cells via specific ligands, enabling highly targeted destruction of cancer cells while minimizing damage to healthy tissue.
• Potential of 177Lu-PNT2002 for Chemotherapy-Naive mCRPC Patients: 177Lu-PNT2002, a late-stage PSMA-targeted radiotherapeutic candidate, is well-tolerated and holds significant potential in meeting the needs of chemotherapy-naive mCRPC patients.
• Rising Radioligand Therapies Clinical Trial Activities: The expected launch of radioligand therapies market are expected to change in the coming years due to the launch of emerging therapies such as Novartis (177Lu-PSMA-617, 225Ac PSMA 617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359), Curium Pharma (177Lu-PSMA-I&T), Lantheus and Eli Lilly and Company (Lu-PNT2002 and LNTH-1095), Fusion Pharmaceuticals and AstraZeneca (FPI-2265), Clarity Pharmaceuticals (67CU SAR-BBN and 64Cu-SAR-BBN), Bayer (225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, and 225Ac-GPC3), ITM Isotope Technologies (ITM-11), ARTBIO (212Pb-NG001), Convergent Therapeutics (CONV01-a), Perspective Therapeutics (VMT-a-NET, VMT01, and PSV359), PRECIRIX (CAM-FAP-Ac-225), Ariceum Therapeutics (225Ac-SSO110 and ATT001), Nuclidium (NU101 and NU201), and others.

DelveInsight's " Radioligand Therapy Market Size, Target Population, Competitive Landscape, and Market Forecast - 2036" report delivers an in-depth understanding of the radioligand Therapy, historical and forecasted epidemiology, competitive landscape as well as the radioligand Therapy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Radioligand therapy market outlook report provides current Radioligand Therapy Market Treatment practices, emerging drugs, market share of individual Therapy, and current and forecasted 7MM radioligand therapy market size from 2022 to 2036. The Radioligand therapy market report also covers current radioligand therapy treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the Radioligand therapy market's potential.

Radioligand Therapy Treatment Market

Radioligand therapy are a form of targeted nuclear medicine that may recognize and treat diseases such as cancer. Radioligand therapy deliver radiation to certain cancer cells that express specific targets. Radioligand therapy marks a significant advancement in precision oncology, offering a targeted approach to cancer treatment

Radioligand Therapy have 2 primary components the radioisotope and the cell-targeting compound, or ligand which are joined together by a chemical with each other. A radioisotope is a radioactive particle that releases radiation to target cells and destroys them and the targeting ligand is the one that attaches to cells that express specific targets and directs the radioisotope to cells with these targets.

Therapeutic radioisotopes are produced in special nuclear reactors or generators, and then shipped to a production facility where the radioisotope is bonded to the cell-targeting compound. The finished product is then placed in vials, sent through quality testing, packaged into special lead-shielded containers, and shipped directly to the hospital or clinic as a ready-to-use therapy.

The most common forms of radionuclide or radioligand therapy include XOFIGO, PLUVICTO (both for prostate cancer), and ZEVALIN (for lymphomas).

Radioligand Therapy Market

For Radioligand Therapy Treatment. The targeting compound part of radioligand is designed to bind specifically to proteins or receptors that are overexpressed on the surface of cancer cells.

Radioligand therapy generally works in the following ways:

Target Identification: Researchers identify specific proteins or receptors that are overexpressed on the surface of cancer cells. These proteins serve as targets for the radioligand.

Radioligand Development: A targeting molecule (ligand) is developed or selected to bind specifically to the identified target protein or receptor. This ligand is then attached to a radioactive isotope, usually through a chemical linker.

Administration: The radioligand is administered to the patient, typically intravenously. The radioligand circulates in the bloodstream and binds to the target proteins on the surface of cancer cells.

Localization: The radioligand accumulates in the cancer cells, delivering radiation directly to the tumor sites while sparing surrounding healthy tissues.

Radiotherapy: Once localized within the cancer cells, the radioactive isotope emits radiation, which damages the DNA of the cancer cells, leading to their death.

Elimination: Any unbound radioligand is cleared from the body through urine or feces, minimizing exposure to healthy tissues.

One of the advantages of radioligand therapy is its ability to deliver high doses of radiation directly to cancer cells while minimizing damage to surrounding healthy tissues, thus reducing side effects.

Recent Developments in Radioligand Therapy Clinical Trials

• In March 2026, ITM Isotope Technologies Munich SE presented post-hoc subgroup analyses from the Phase 3 ITM-11 COMPETE trial involving patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
• In March 2026, Lantheus Holdings, Inc. announced that the FDA had granted tentative approval to its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of LUTATHERA (lutetium Lu 177 dotatate).
• In January 2026, Zonsen PepLib Biotech Inc. announced a global licensing agreement with Novartis for an undisclosed peptide-based candidate in the radioligand therapy (RLT) space. As part of the deal, Novartis has secured exclusive worldwide rights and will oversee the asset's development and commercialization.
• In January 2026, Swiss Rockets AG and Alloy Therapeutics, Inc. entered into a Master Research Agreement (MRA) to initiate a multi-target partnership focused on the discovery and development of next-generation radioligand therapeutics (RLTs) for oncology. The collaboration will be carried out through Swiss Rockets' radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG.
• In January 2026, ARTBIO, Inc. began dosing two U.S.-based patient cohorts in the ARTISAN Phase 1 trial of AB001, an alpha radioligand therapy designed to treat metastatic castration-resistant prostate cancer (mCRPC), enrolling patients with and without prior Lu177-PSMA targeted therapy exposure.
• In November 2025, ITM Isotope Technologies Munich SE announced that the U.S. Food and Drug Administration had completed its filing review and accepted the company's New Drug Application (NDA) for n.c.a. 177Lu-edotreotide, also referred to as ITM-11.

ASCO 2026 Insights

• Convergent Therapeutics reported encouraging interim Phase 2 results for CONV01-a (Ac-225 rosopatamab tetraxetan) in patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received Lu-177-PSMA therapy. The study demonstrated promising anti-tumor activity, with a 40% PSA response rate (>=50% decline) and a median radiographic progression-free survival (rPFS) of 8.4 months at the target dose.
• Telix Pharmaceuticals presented Part 1 data from the Phase 3 ProstACT Global trial evaluating TLX591-Tx (lutetium-177 rosopatamab tetraxetan) in combination with standard-of-care therapies for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The study demonstrated an acceptable safety and tolerability profile, with no new safety concerns identified and favorable radiation dosimetry findings.
• The first-in-human Phase I trial (NCT07006727) evaluating [225Ac]Ac-ETN029, a novel DLL3-targeted radioligand therapy, in patients with advanced DLL3-expressing solid tumors, including small cell lung cancer (SCLC) and neuroendocrine carcinomas, was presented at ASCO 2026.
• Sinotau showcased clinical data for XTR022 ([225Ac]Ac-XT381) in a poster presentation. The trial examined the safety profile, tolerability, and preliminary antitumor activity of the alpha-particle radioligand therapy in previously treated patients with PSMA-positive mCRPC.
• Novartis reported that Pluvicto(TM) (lutetium Lu 177 vipivotide tetraxetan), combined with standard of care (androgen receptor pathway inhibitor [ARPI] plus androgen deprivation therapy [ADT]), demonstrated consistent improvements in radiographic progression-free survival (rPFS) across major patient subgroups versus standard of care alone in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The findings from the PSMAddition study were presented during an oral session at the 2026 ASCO Annual Meeting.
• Johnson & Johnson reported final Phase 3 PROTEUS study results demonstrating that investigational apalutamide combined with androgen deprivation therapy (ADT), administered for six months before and after prostate cancer surgery, significantly improved both short- and long-term clinical outcomes in patients with high-risk localized or locally advanced prostate cancer. The study successfully achieved both of its primary endpoints.

Radioligand Therapy Drug Analysis

The drug chapter segment of the Radioligand therapy market reports encloses a detailed analysis of radioligand therapy marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the radioligand therapy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug the latest news and press releases.

Radioligand Therapy Marketed Drugs

• LUTATHERA (lutetium LU 177 dotatate): AAA USA/Novartis

LUTATHERA is the very first therapy approved specifically for children with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It is now offering new hope to young patients living with this rare cancer. LUTATHERA is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs.

LUTATHERA is a radioactive drug that works by binding to a part of a cell called a somatostatin receptor, which may be present in certain tumors. After binding to the receptor, the drug enters the cell allowing radiation to cause damage to the tumor cells.

• PLUVICTO (lutetium lu-177 vipivotide tetraxetan): Novartis

PLUVICTO is the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) that combines a targeting compound (ligand) with a therapeutic radioisotope.

The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177 which is linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC. Upon binding of lutetium Lu 177 vipivotide tetraxetan to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, as well as to surrounding cells, and induces DNA damage which can lead to cell death.

Radioligand Therapy Emerging Drugs

• 177Lu-PSMA-I&T: Curium

177Lu-PSMA-I&T targets prostate-specific membrane antigen, which is expressed in greater than 85% of prostate cancer cells. Because the medicine is highly selective for that antigen, the radioisotope only targets these cancer cells. Once the medicine attaches itself to the cancer cell, the radioisotope is internalized within the cancer cell, where the radioactive properties break the DNA strand of the cancer cells, thus killing the prostate cancer cell.

• Lu-PNT2002: Eli Lilly/Point biopharma

Lu-PNT2002 is a PSMA-targeted, lutetium 177-based radioligand therapy candidate that combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added lutetium-177.

Lantheus Holdings has the in-licensed exclusive worldwide commercialization rights (excluding certain Asian territories) to 177Lu-PNT2002 from POINT in December of 2022. In April of 2023, the FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC.

Radioligand Therapy Market Outlook

The radioligand therapy market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of radioligand Therapy, the increasing number of radioligand Therapy that are under clinical trials, and the increasing interest of major pharmaceutical companies toward it.

Radioligand Therapy (RLT) are currently an emerging modality of treatment for different types of cancers. They have been shown to improve progression-free survival and quality of life in neuroendocrine tumors and overall survival in metastatic castration-resistant prostate cancer and have recently been introduced into cancer care guidelines for these types of tumors. In addition, radioligand Therapy have the potential to treat other forms of cancer, including aggressive or rare types, in particular metastatic disease without effective treatment options.

Currently, Various radioligand Therapy such as LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN are approved by the US FDA. LUTATHERA was the first approved radioligand therapy by the FDA for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients but recently it got its approval for the treatment of pediatric patients also.

The FDA also approved PLUVICTO in 2022 and it became the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) and recorded sales of more than USD 950 million.

NOVARTIS has two Radioligand Therapy already available to patients around the world, numerous RLTs in their pipeline and 15+ Radioligand Therapymclinical trials are underway or planned. Various acquisitions of the Radioligand therapy companies that have their radioligand Therapy in the clinical study phase have taken place such as AstraZeneca having acquired Fusion Pharmaceutical which has its radioligand therapy FPI-2265 in phase II/III of clinical studies.

Several key Radioligand therapy companies, including AstraZeneca, Eli Lilly, Curium, and others, are involved in developing drugs for radioligand Therapy for various indications such as prostate cancer, pancreatic cancer, and others. Overall, this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of radioligand Therapy and define their role in the therapy of cancer.

Radioligand Therapy Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging Radioligand therapy therapies expected to be launched in the Radioligand therapy market during 2020-2034.

Radioligand Therapy Clinical Trials Analysis

The Radioligand Therapy Market Report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key Radioligand therapy companies involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for radioligand Therapy market growth over the forecasted period.

Radioligand therapy Pipeline Activities

The Radioligand Therapy Market Report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging radioligand Therapy.

The increasing strategic collaborations among major Radioligand therapy companies to enhance the growth of their pipeline products are anticipated to drive Radioligand therapy market expansion. For example, in July 2024 Eli Lilly completed its acquisition of radiopharmaceutical company Point Biopharma for approximately $1.4 billion.

Upon this acquisition, Jacob Van Naarden who is President at Loxo (Lilly) said "Next-generation radioligand Therapy hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of Point Biopharma"

Latest KOL Views on Radioligand therapy market

To keep up with current and future Radioligand therapy market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on radioligand Therapy' evolving treatment landscape, patient reliance on conventional Therapy, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM.

Their opinion helps understand and validate current and emerging therapy treatment patterns or radioligand therapy market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the Radioligand therapy market and the unmet needs.

Radioligand Therapy Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of Therapy are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Radioligand Therapy Market Access and Reimbursement

Reimbursement for Radioligand Therapy market size has been universal in the United States and even in Europe. In the UK, NICE recommended Lutetium (177Lu) oxodotreotide within its marketing authorization, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs) in adults. It is recommended only if the company provides it according to the commercial arrangement. NETs can affect the pancreas and gastrointestinal tissue and are difficult to diagnose and treat. Current treatment options include everolimus, sunitinib, and best supportive care. Clinical trial evidence shows that lutetium (177Lu) oxodotreotide (referred to as lutetium) is effective for treating somatostatin receptor-positive gastrointestinal and pancreatic NETs. Indirect comparison with everolimus, sunitinib, and best supportive care suggests lutetium is effective for treating gastrointestinal and pancreatic NETs in people with progressive disease.

For treating pancreatic NETs, lutetium meets NICE's end-of-life criteria. Compared with everolimus, sunitinib, and best supportive care, the cost-effectiveness estimates are within the range NICE normally considers acceptable. So lutetium can be recommended for treating pancreatic NETs.

For treating gastrointestinal NETs, lutetium does not meet the end-of-life criteria because the life expectancy for this form of the disease is between 5 and 6 years. But it can be recommended because the most plausible cost-effectiveness estimate is within what NICE normally considers acceptable and treatment options for gastrointestinal NETs are limited.

The Radioligand therapy market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved Therapy, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Radioligand Therapy Market Report

• The Radioligand Therapy Market Insights Report covers a segment of key events, an executive summary, and a descriptive overview of radioligand Therapy, explaining its mechanism, and Therapy (current and emerging).
• Comprehensive insight into the Competitive Landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging Therapy and the elaborative profiles of late-stage and prominent Therapy will impact the current landscape.
• A detailed review of the Radioligand Therapy market, historical and forecasted market size, market share by Therapy, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Radioligand therapy market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis expert insights/KOL views, and treatment preferences that help shape and drive the 7MM radioligand Therapy market.

Radioligand Therapy Market Report Insights

• Radioligand Therapy Targeted Patient Pool
• Radioligand Therapy Therapeutic Approaches
• Radioligand Therapy Pipeline Analysis
• Radioligand Therapy Market Size
• Radioligand therapy Market Trends
• Existing and Future Radioligand therapy Market Opportunity

Radioligand Therapy Market Report Key Strengths

• Eleven years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake
• Key Radioligand therapy Market Forecast Assumptions

Radioligand Therapy Market Report Assessment

• Current Radioligand therapy Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Radioligand therapy Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions answered in the Radioligand therapy market report

• What was the Radioligand therapy market size, the market size by Therapy, market share (%) distribution, and what would it look like in 2036? What are the contributing factors for this growth?
• Which Radioligand therapy is going to be the largest contributor in 2036?
• Which is the most lucrative Radioligand therapy market?
• Which drug type segment accounts for maximum radioligand therapy sales?
• What are the pricing variations among different geographies for approved Therapy?
• How has the reimbursement landscape for radioligand Therapy evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with radioligand Therapy? What will be the growth opportunities across the 7MM for the patient population on radioligand Therapy?
• What are the key factors hampering the growth of the radioligand Therapy market?
• What are the indications for which recent novel Therapy and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the Therapy for radioligand Therapy?
• What is the cost burden of approved Radioligand therapy on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved Radioligand therapy?

Reasons to buy the Radioligand Therapy Market Outlook Report

• The Radioligand Therapy Market Insights Report will help develop business strategies by understanding the latest trends and changing dynamics driving the radioligand Therapy Market.
• Understand the existing Radioligand therapy market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming Radioligand therapy companies in the Radioligand therapy market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging Therapy under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved Therapy, barriers to accessibility of expensive off-label Therapy, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Radioligand therapy market so that the upcoming Radioligand therapy companies can strengthen their development and launch strategy.